Table 3.
The relationship of MET and FASN with the clinical pathological features in TNBC.
| Clinical pathological features | n | MET | chi-square value | p value | FASN | chi-square value | p value | |||
|---|---|---|---|---|---|---|---|---|---|---|
| positive | negative | positive | negative | |||||||
| Tumor size (cm) | ≤2 | 55 | 29 (52.7) | 26 (47.3) | 1.648 | 0.439 | 30 (54.5) | 25 (45.5) | 4.114 | 0.128 |
| 2–5 | 124 | 78 (62.9) | 46 (37.1) | 87 (70.2) | 37 (29.8) | |||||
| ≥5 | 39 | 23 (59.0) | 16 (41.0) | 25 (64.1) | 14 (35.9) | |||||
| Lymph node | metastasis | 66 | 46 (69.7) | 20 (30.3) | 3.983 | 0.046 | 50 (75.8) | 16 (24.2) | 4.701 | 0.030 |
| no-metastasis | 152 | 84 (55.3) | 68 (44.7) | 92 (60.5) | 60 (39.5) | |||||
| Pathological TNM | I | 50 | 22 (44.0) | 28 (56.0) | 6.643 | 0.036 | 21 (42.0) | 29 (58.0) | 16.30 | 0.001 |
| II | 110 | 70 (63.6) | 40 (36.4) | 79 (71.8) | 31 (28.2) | |||||
| III | 58 | 38 (65.5) | 20 (34.5) | 42 (72.4) | 16 (27.6) | |||||
| Pathologic Stage | I | 15 | 5 (33.3) | 10 (66.7) | 6.365 | 0.041 | 4 (26.7) | 11 (73.3) | 11.18 | 0.004 |
| II | 129 | 75 (58.1) | 54 (41.9) | 85 (65.9) | 44 (34.1) | |||||
| III | 74 | 50 (67.6) | 24 (32.4) | 53 (71.6) | 21 (28.4) | |||||
| Diabetes | Positive | 29 | 16 (55.2) | 13 (44.8) | 0.276 | 0.599 | 24 (82.8) | 5 (17.2) | 4.574 | 0.032 |
| Negative | 189 | 114 (60.3) | 75 (39.7) | 118 (62.4) | 71 (37.6) | |||||
| Body mass index | <18.5 | 4 | 1 (25.0) | 3 (75.0) | 2.053 | 0.561 | 0 (0.0) | 4 (100) | 13.33 | 0.004 |
| 18.5–23.9 | 102 | 62 (60.8) | 40 (41.2) | 60 (58.8) | 42 (41.2) | |||||
| 24–27.9 | 70 | 42 (60.0) | 28 (40.0) | 49 (70.0) | 21 (30.0) | |||||
| ≥28 | 42 | 25 (59.5) | 17 (40.5) | 33 (78.6) | 9 (21.4) | |||||
Since the P value is less than 0.05, we highlighted it in bold.